intralesional
0
Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV
0

Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV

Highlight Therapeutics, a clinical‑stage biotechnology company developing immune activators to transform the treatment of skin tumors, today ...

admin admin October 13, 2026
READ MORE +

No widgets added. You can disable footer widget area in theme options - footer options

Daily Deals
Logo
Register New Account
Compare items
  • Total (0)
Compare
0
Shopping cart